$NVCR
NovoCure Ltd Stock $nvcr

$nvcr Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000164511320000068 Filed on April 30, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$101.8M	$73.31M
YoY Change	38.9%	40.64%
Cost Of Revenue	$24.50M	$19.81M
YoY Change	23.63%	8.87%
Gross Profit	$77.33M	$53.50M
YoY Change	44.56%	57.86%
Gross Profit Margin	75.94%	72.97%
Selling, General & Admin	$55.44M	$42.57M
YoY Change	30.23%	19.92%
% of Gross Profit	71.69%	79.58%
Research & Development	$25.27M	$17.04M
YoY Change	48.29%	53.53%
% of Gross Profit	32.68%	31.86%
Depreciation & Amortization	$1.890M	$1.930M
YoY Change	-2.07%	-12.27%
% of Gross Profit	2.44%	3.61%
Operating Expenses	$80.71M	$59.61M
YoY Change	35.39%	27.92%
Operating Profit	-$3.381M	-$6.118M
YoY Change	-44.74%	-51.74%
Interest Expense	-$2.400M	-$2.400M
YoY Change	0.0%	-51.02%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$5.813M	-$8.489M
YoY Change	-31.52%	-51.49%
Income Tax	-$9.765M	$3.661M
% Of Pretax Income
Net Earnings	$3.952M	-$12.15M
YoY Change	-132.53%	-41.37%
Net Earnings / Revenue	3.88%	-16.57%
Basic Earnings Per Share	$0.04	-$0.13
Diluted Earnings Per Share	$0.04	-$0.13
COMMON SHARES
Basic Shares Outstanding	99.88M shares	94.81M shares
Diluted Shares Outstanding	108.1M shares	94.81M shares

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$331.3M	$256.6M
YoY Change	29.11%	18.63%
Cash & Equivalents	$181.9M	$154.2M
Short-Term Investments	$149.3M	$104.5M
Other Short-Term Assets	$800.0K	$2.100M
YoY Change	-61.9%	-4.55%
Inventory	$22.50M	$24.10M
Prepaid Expenses
Receivables	$65.14M	$39.20M
Other Receivables	$42.50M	$13.60M
Total Short-Term Assets	$462.2M	$335.7M
YoY Change	37.68%	18.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.778M	$29.60M
YoY Change	-66.97%	65.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.824M	$5.000M
YoY Change	-3.52%	85.19%
Total Long-Term Assets	$40.27M	$34.60M
YoY Change	16.39%	67.15%
TOTAL ASSETS
Total Short-Term Assets	$462.2M	$335.7M
Total Long-Term Assets	$40.27M	$34.60M
Total Assets	$502.4M	$370.3M
YoY Change	35.69%	22.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$40.40M	$29.90M
YoY Change	35.12%	54.12%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$84.20M	$70.90M
YoY Change	18.76%	58.26%
LONG-TERM LIABILITIES
Long-Term Debt	$149.5M	$149.3M
YoY Change	0.11%	0.07%
Other Long-Term Liabilities	$267.0K	$23.60M
YoY Change	-98.87%	594.12%
Total Long-Term Liabilities	$176.3M	$172.9M
YoY Change	1.96%	13.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$84.20M	$70.90M
Total Long-Term Liabilities	$176.3M	$172.9M
Total Liabilities	$260.5M	$243.9M
YoY Change	6.81%	23.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$646.9M
YoY Change
Common Stock	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$241.9M	$126.4M
YoY Change
Total Liabilities & Shareholders Equity	$502.4M	$370.3M
YoY Change	35.69%	22.01%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	$3.952M	-$12.15M
YoY Change	-132.53%	-41.37%
Depreciation, Depletion And Amortization	$1.890M	$1.930M
YoY Change	-2.07%	-12.27%
Cash From Operating Activities	$1.957M	-$4.315M
YoY Change	-145.35%	-74.35%
INVESTING ACTIVITIES
Capital Expenditures	$3.112M	$2.325M
YoY Change	33.85%	215.47%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$1.340M
YoY Change	-100.0%	436.0%
Cash From Investing Activities	-$3.112M	-$989.0K
YoY Change	214.66%	-46.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$0.00
YoY Change
Debt Paid & Issued, Net	$8.000K	$8.000K
YoY Change	0.0%	-99.99%
Cash From Financing Activities	$4.503M	$16.97M
YoY Change	-73.46%	-67.18%
NET CHANGE
Cash From Operating Activities	$1.957M	-$4.315M
Cash From Investing Activities	-$3.112M	-$989.0K
Cash From Financing Activities	$4.503M	$16.97M
Net Change In Cash	$3.289M	$11.41M
YoY Change	-71.16%	-65.48%
FREE CASH FLOW
Cash From Operating Activities	$1.957M	-$4.315M
Capital Expenditures	$3.112M	$2.325M
Free Cash Flow	-$1.155M	-$6.640M
YoY Change	-82.61%	-62.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001645113
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-37565
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	NovoCure Limited
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	Y9
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1057807
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	No. 4 The Forum
CY2020Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Grenville Street
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	St. Helier
CY2020Q1	dei	Entity Address Country EntityAddressCountry	JE
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	JE2 4UF
CY2020Q1	dei	City Area Code CityAreaCode	44 (0) 15
CY2020Q1	dei	Trading Symbol TradingSymbol	NVCR
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	3475 6700
CY2020Q1	dei	Security12b Title Security12bTitle	Ordinary Shares, no par value
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	100440295	shares
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	181919000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177321000	USD
CY2020Q1	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	149349000	USD
CY2019Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	148769000	USD
CY2020Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	786000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2095000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	65139000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	58859000	USD
CY2020Q1	nvcr	Receivables And Prepaid Expenses ReceivablesAndPrepaidExpenses	42483000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4824000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4904000	USD
CY2019Q4	nvcr	Receivables And Prepaid Expenses ReceivablesAndPrepaidExpenses	29202000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	22502000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	23701000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	462178000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	439947000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9778000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9342000	USD
CY2020Q1	nvcr	Field Equipment Net Noncurrent FieldEquipmentNetNoncurrent	8467000	USD
CY2019Q4	nvcr	Field Equipment Net Noncurrent FieldEquipmentNetNoncurrent	7684000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17201000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17571000	USD
CY2020Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	40270000	USD
CY2019Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	39501000	USD
CY2020Q1	us-gaap	Assets Assets	502448000	USD
CY2019Q4	us-gaap	Assets Assets	479448000	USD
CY2020Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	40408000	USD
CY2019Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	36925000	USD
CY2020Q1	nvcr	Other Accounts Payable Lease Liabilites And Accrued Expenses Current OtherAccountsPayableLeaseLiabilitesAndAccruedExpensesCurrent	43795000	USD
CY2019Q4	nvcr	Other Accounts Payable Lease Liabilites And Accrued Expenses Current OtherAccountsPayableLeaseLiabilitesAndAccruedExpensesCurrent	49386000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	84203000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	86311000	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	149465000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	149424000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	8772000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	7807000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13274000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14140000	USD
CY2020Q1	nvcr	Employee Related Liabilities Non Current EmployeeRelatedLiabilitiesNonCurrent	4519000	USD
CY2019Q4	nvcr	Employee Related Liabilities Non Current EmployeeRelatedLiabilitiesNonCurrent	3754000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	267000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	222000	USD
CY2020Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	176297000	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	175347000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	260500000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	261658000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	100362973	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100362973	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	99528435	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	99528435	shares
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	892510000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	871442000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3629000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25271000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2767000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-646933000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-650885000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	241948000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	217790000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	502448000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	479448000	USD
CY2020Q1	us-gaap	Revenues Revenues	101828000	USD
CY2019Q1	us-gaap	Revenues Revenues	73309000	USD
CY2019	us-gaap	Revenues Revenues	351318000	USD
CY2020Q1	us-gaap	Cost Of Revenue CostOfRevenue	24496000	USD
CY2019Q1	us-gaap	Cost Of Revenue CostOfRevenue	19814000	USD
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	88606000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	77332000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	53495000	USD
CY2019	us-gaap	Gross Profit GrossProfit	262712000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17042000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79003000	USD
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	28834000	USD
CY2019Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	22333000	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	96675000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26608000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20238000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	87948000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	80713000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	59613000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	263626000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3381000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6118000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-914000	USD
CY2020Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	2432000	USD
CY2019Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	2371000	USD
CY2019	us-gaap	Interest And Debt Expense InterestAndDebtExpense	7910000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5813000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8489000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8824000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9765000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3661000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1594000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	3952000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-12150000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-7230000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99877567	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94811282	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97237549	shares
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108100623	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94811282	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97237549	shares
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	3952000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-12150000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-7230000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-200000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-261000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-304000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	662000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	81000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	1063000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3090000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12492000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8597000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	217790000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16557000	USD
CY2020Q1	nvcr	Stock Issued During Period Value Exercise Of Options And Vested Rs Us StockIssuedDuringPeriodValueExerciseOfOptionsAndVestedRSUs	4511000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-862000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	3952000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	241948000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	112259000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9649000	USD
CY2019Q1	nvcr	Stock Issued During Period Value Exercise Of Options And Vested Rs Us StockIssuedDuringPeriodValueExerciseOfOptionsAndVestedRSUs	16978000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-11000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-342000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-12150000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	126394000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	3952000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-12150000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-7230000	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1888000	USD
CY2019Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1929000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	8460000	USD
CY2020Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6000	USD
CY2019Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	75000	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	398000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	16557000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9649000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	52416000	USD
CY2020Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	7000	USD
CY2019Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	917000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	19718000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2036000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	36496000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4315000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	26620000	USD
CY2020Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-539000	USD
CY2019Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-578000	USD
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-2176000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1147000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1583000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1159000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1235000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	86000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3446000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2339000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2246000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	16883000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-225000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1781000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-7006000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1957000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3112000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2325000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10485000	USD
CY2020Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	0	USD
CY2019Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	105661000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	420661000	USD
CY2020Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0	USD
CY2019Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	104325000	USD
CY2019	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	461843000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3112000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-989000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-51667000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2467000	USD
CY2020Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	8000	USD
CY2019Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	8000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	31000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4511000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16978000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	59245000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4503000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16970000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61681000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-59000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-261000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3289000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11405000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	36660000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179416000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	142756000	USD
CY2020Q1	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	149951000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179416000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	142756000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	182705000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154161000	USD
CY2020Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2209000	USD
CY2019Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3033000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	11241000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	3415000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	3379000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	13699000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	783000	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	15733000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	22943000	USD
CY2020Q1	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	149349000	USD
CY2019Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	148769000	USD
CY2020Q1	us-gaap	Cash Cash	8192000	USD
CY2019Q4	us-gaap	Cash Cash	18377000	USD
CY2020Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	173727000	USD
CY2019Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	158944000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	181919000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177321000	USD
CY2019Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	148738000	USD
CY2020Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3889000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3912000	USD
CY2020Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	7498000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6482000	USD
CY2020Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	11115000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	13308000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	22502000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	23701000	USD
CY2020Q1	us-gaap	Contractual Obligation ContractualObligation	1387000	USD
CY2019Q4	us-gaap	Contractual Obligation ContractualObligation	1390000	USD
CY2020Q1	us-gaap	Deposits Assets DepositsAssets	1612000	USD
CY2019Q4	us-gaap	Deposits Assets DepositsAssets	1557000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10350810	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.40
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	671530	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	69.37
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	291088	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	15.52
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	6025	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	41.39
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10725227	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.58
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4572967	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	16.17
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	291088	shares
CY2020Q1	nvcr	Ordinary Shares Issued Upon Option Exercise OrdinarySharesIssuedUponOptionExercise	291088	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1474395	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	30.26
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	3747545	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	54.07
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	543450	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	22.10
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	3194	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	52.84
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	4675296	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	50.28
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16557000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9649000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	52416000	USD
CY2020Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	8223056	shares
CY2020Q1	us-gaap	Noncurrent Assets NoncurrentAssets	18245000	USD
CY2019Q4	us-gaap	Noncurrent Assets NoncurrentAssets	17026000	USD
CY2020Q1	us-gaap	Revenues Revenues	101828000	USD
CY2019Q1	us-gaap	Revenues Revenues	73309000	USD
CY2019	us-gaap	Revenues Revenues	351318000	USD
CY2020Q1	us-gaap	Revenues Revenues	101828000	USD
CY2019Q1	us-gaap	Revenues Revenues	73309000	USD
CY2020Q1	us-gaap	Cost Of Revenue CostOfRevenue	24496000	USD
CY2019Q1	us-gaap	Cost Of Revenue CostOfRevenue	19814000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	77332000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	53495000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25271000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17042000	USD
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	28834000	USD
CY2019Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	22333000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26608000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20238000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	80713000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	59613000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3381000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6118000	USD
CY2020Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	2432000	USD
CY2019Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	2371000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5813000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8489000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9765000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3661000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	3952000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-12150000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99877567	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94811282	shares
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108100623	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94811282	shares
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16557000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9649000	USD

Files In Submission

Name	View Source	Status
0001645113-20-000068-index-headers.html	Edgar Link	pending
0001645113-20-000068-index.html	Edgar Link	pending
0001645113-20-000068.txt	Edgar Link	pending
0001645113-20-000068-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvcr-20200331.htm	Edgar Link	pending
nvcr-20200331.xsd	Edgar Link	pending
nvcr-20200331xexx311.htm	Edgar Link	pending
nvcr-20200331xexx312.htm	Edgar Link	pending
nvcr-20200331xexx321.htm	Edgar Link	pending
nvcr-20200331xexx322.htm	Edgar Link	pending
nvcr-20200331_cal.xml	Edgar Link	unprocessable
nvcr-20200331_def.xml	Edgar Link	unprocessable
nvcr-20200331_g1.jpg	Edgar Link	pending
nvcr-20200331_htm.xml	Edgar Link	completed
nvcr-20200331_lab.xml	Edgar Link	unprocessable
nvcr-20200331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVCR
NovoCure Ltd Stock $nvcr

2020 Q1 Form 10-Q Financial Statement

#000164511320000068 Filed on April 30, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVCR NovoCure Ltd Stock $nvcr

2020 Q1 Form 10-Q Financial Statement

#000164511320000068 Filed on April 30, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVCR
NovoCure Ltd Stock $nvcr